MR revealed that genetically proxied NEU1 inhibition reduced cervical cancer risk (<i>OR</i> = 0.736, 95% CI: 0.566-0.958), with CD25 on CD45RA<sup>+</sup> CD4<sup>+</sup> non-regulatory T cells mediating 28.458% of the total effect.<h4>Conclusion</h4>By integrating genetic causal inference, <i>in vitro</i> experiments, and network pharmacology, our study systematically reveals that celecoxib may exert therapeutic effects by targeting against cervical cancer by targeting NEU1 and modulating CD25 on CD45RA<sup>+</sup> CD4<sup>+</sup> non-regulatory T cell-related immune pathways. This evidence concerns the gene CD4 and cervical carcinoma.